Clinical Trial Update: Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating 0.03% tacrolimus ointment for atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tacrolimus Ointment 0.03% (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Dermatitis, Atopic | Phase 3 | Status: COMPLETED